• Western blot analysis of lysates from HepG2 and COLO205 cells, using CDKL4 Antibody. The lane on the right is blocked with the synthesized peptide.
  • Immunofluorescence analysis of HeLa cells, using CDKL4 Antibody. The picture on the right is blocked with the synthesized peptide.
  • Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using CDKL4 Antibody. The picture on the right is blocked with the synthesized peptide.
  • Western blot analysis of various cells using CdkL4 Polyclonal Antibody diluted at 1:500

Anti-CDKL4 antibody (266-315 aa) (STJ92207)

SKU:
STJ92207

Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Rat/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Cyclin-dependent kinase-like 4 (266-315 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IHC 1:100-1:300
IF 1:200-1:1000
ELISA 1:40000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: CDKL4
Gene ID: 344387
Uniprot ID: CDKL4_HUMAN
Immunogen Region: 266-315 aa
Specificity: CdkL4 Polyclonal Antibody detects endogenous levels of CdkL4 protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human CDKL4 at the amino acid range 266-315
Cellular Localisation Cytoplasm
Alternative Antibody Names Anti-Cyclin-Dependent Kinase-Like 4 antibody
Anti-CDKL4 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance